TapImmune, Inc. announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin(R)-based therapy and are at risk of disease recurrence.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.87 USD | -2.21% | -6.17% | -11.45% |
07-01 | Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index | CI |
07-01 | Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.45% | 43.44M | |
+23.50% | 47.07B | |
+46.06% | 42.06B | |
-5.16% | 39.98B | |
+36.37% | 33.02B | |
-7.79% | 27.9B | |
+18.06% | 27.63B | |
+47.29% | 14.37B | |
+41.91% | 13.45B | |
-1.02% | 12.03B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- TapImmune, Inc. Announces Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens